Circulating galectin-3 correlates with angiogenetic factors, indicators of nutritional condition and systemic inflammation in patients with thyroid cancer
-
- Shimura Tatsuo
- Department of Cancer Biology and Electronics, Fukushima Medical University
-
- Shibata Masahiko
- Department of Gastrointestinal Oncology, Saitama Medical University International Medical Center
-
- Gonda Kenji
- Department of Gastrointestinal Oncology, Saitama Medical University International Medical Center
-
- Nakajima Takahiro
- Department of Organ Regulatory Surgery, Fukushima Medical University
-
- Chida Shun
- Department of Organ Regulatory Surgery, Fukushima Medical University
-
- Noda Masaru
- Department of Organ Regulatory Surgery, Fukushima Medical University
-
- Suzuki Satoshi
- Department of Thyroid and Endocrinology, Fukushima Medical University
-
- Nakamura Izumi
- Department of Thyroid and Endocrinology, Fukushima Medical University
-
- Nakano Keiichi
- Department of Thyroid and Endocrinology, Fukushima Medical University
-
- Fukushima Toshihiko
- Department of Thyroid and Endocrinology, Fukushima Medical University
-
- Suzuki Shinichi
- Department of Thyroid and Endocrinology, Fukushima Medical University
-
- Takenoshita Seiichi
- Department of Organ Regulatory Surgery, Fukushima Medical University
この論文をさがす
抄録
Background and Aims: Several investigators have reported the significance of circulating galectin-3 in thyroid cancer patients. However, the precise meaning of circulating galectin-3 remains unclear. The aim of this study was to investigate the relationships between serum galectin-3 levels and angiogenetic factors, and nutritional and inflammatory indicators in patients with thyroid cancer. <br>Materials and Methods: Sixty-one patients with thyroid tumors were enrolled, comprising 47 pre-treatment thyroid cancer patients and 14 patients with benign thyroid diseases. Galectin-3, interleukin (IL)-6, vascular endothelial growth factor, granulocyte colony-stimulating factor (G-CSF), soluble form of intercellular adhesion molecule-1 (sICAM-1), retinol binding protein, prealbumin, albumin, and transferrin were measured. C-reactive protein (CRP), neutrophil count, lymphocyte count, and neutrophil/lymphocyte ratio (NLR) were also investigated. <br>Results: The amounts of circulating galectin-3 in benign disease and thyroid cancer were significantly higher than those of healthy volunteers (P < 0.001). Analysis of galectin-3 performance in distinguishing malignant disease from benign disease using a receiver operating characteristic curve revealed that the area under the curve was 0.555. There were statistically significant correlations between the circulating amount of galectin-3 and IL6, G-CSF, and sICAM-1. Serum galectin-3 showed statistically significant correlations with albumin, prealbumin, and transferrin. Circulating galectin-3 exhibited strong correlations with CRP, neutrophil count, lymphocyte count, and NLR. <br>Conclusions: Galectin-3 may be one of the key factors in the regulation of angiogenesis, inflammation, and nutrition.
収録刊行物
-
- Annals of Cancer Research and Therapy
-
Annals of Cancer Research and Therapy 24 (1), 35-40, 2016
日本癌病態治療研究会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680165418368
-
- NII論文ID
- 130005142080
-
- ISSN
- 18805469
- 13446835
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可